CR
CRL.US Charles River Laboratories
- Market cap
- USD 16.2B
- P/E
- 367.4x
- P/B
- 5.06x
- ROE
- 13.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CRL.US undervalued?
Graham numberThe Graham number of Charles River Laboratories cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Charles River Laboratories fundamental analysis
No fundamental analysis for Charles River Laboratories yet.
Charles River Laboratories stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical dru…
Full company profileCharles River Laboratories financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Charles River Laboratories annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.68B | 1.86B | 2.27B | 2.62B | 2.92B | 3.54B | 3.98B | 4.13B | 4.05B | 4.02B | 3.98B |
| Gross Profit | 644M | 701M | 840M | 958M | 1.07B | 1.33B | 1.46B | 1.50B | 1.33B | 1.23B | 1.33B |
| Operating Income | 238M | 288M | 331M | 351M | 433M | 590M | 651M | 617M | 227M | 508M | 590M |
| EBITDA | 377M | 458M | 507M | 563M | 768M | 820M | 986M | 1.03B | 581M | 411M | 647M |
| Net Income | 155M | 123M | 226M | 252M | 364M | 391M | 486M | 475M | 10.3M | -144M | 422M |
| EPS | 3.23 | 2.54 | 4.62 | 5.07 | 7.20 | 7.60 | 9.48 | 9.22 | 0.20 | -2.91 | 8.69 |
| Balance Sheet | |||||||||||
| Total Assets | 2.71B | 2.93B | 3.86B | 4.69B | 5.49B | 7.02B | 7.60B | 8.20B | 7.53B | 7.14B | 7.45B |
| Total Liabilities | 1.86B | 1.87B | 2.52B | 3.03B | 3.35B | 4.43B | 4.58B | 4.54B | 4.02B | 3.92B | 4.18B |
| Shareholders' Equity | 837M | 1.05B | 1.32B | 1.63B | 2.11B | 2.53B | 2.98B | 3.60B | 3.46B | 3.16B | 3.23B |
| Cash & Short-term Investments | 118M | 164M | 195M | 239M | 229M | 246M | 234M | 277M | 195M | 214M | 200M |
| Total Debt | 1.24B | 1.15B | 1.70B | 2.02B | 2.16B | 3.21B | 3.10B | 3.07B | 2.72B | 3.07B | 2.85B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 298M | 316M | 441M | 481M | 547M | 761M | 620M | 684M | 735M | 738M | 633M |
| Capital Expenditure | 55.3M | 82.4M | 140M | 141M | 167M | 229M | 325M | 319M | 233M | 219M | 178M |
| Free Cash Flow | 243M | 234M | 301M | 340M | 380M | 532M | 295M | 365M | 502M | 518M | 455M |
| Ratios | |||||||||||
| ROE | 18.5% | 11.8% | 17.2% | 15.4% | 17.2% | 15.4% | 16.3% | 13.2% | 0.3% | -4.6% | 13.1% |
| ROA | 5.7% | 4.2% | 5.9% | 5.4% | 6.6% | 5.6% | 6.4% | 5.8% | 0.1% | -2.0% | 5.7% |
| Net Profit Margin | 9.2% | 6.6% | 10.0% | 9.6% | 12.5% | 11.0% | 12.2% | 11.5% | 0.3% | -3.6% | 10.6% |
| Debt to Equity | 1.48x | 1.10x | 1.29x | 1.24x | 1.02x | 1.26x | 1.04x | 0.85x | 0.79x | 0.97x | 0.88x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Charles River Laboratories dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 25.6M | 0.50 | 5.4% |
| 2022 | - | - | - |
| 2021 | USD 45.7M | 0.89 | 11.7% |
| 2020 | USD 46.6M | 0.92 | 12.8% |
| 2019 | USD 34.5M | 0.70 | 13.7% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Charles River Laboratories
- Insiders 0.47%
- Institutions 99.53%
- Public & others 0.00%
- Shares outstanding 47.9M
- Free float 47.4M
Top funds holding CRL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Contrafund | 2.07M | 4.31% | +13.18% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.52M | 3.16% | -0.93% | Sep 2026 |
| Vanguard 500 Index Investor | 1.25M | 2.61% | -2.09% | Sep 2026 |
| Vanguard Small Cap Index | 1.07M | 2.24% | -3.04% | Sep 2026 |
| Oakmark Select Investor | 1.01M | 2.11% | -32.36% | Sep 2026 |
| Invesco S&P 500® Equal Weight ETF | 709K | 1.48% | +0.16% | Oct 2026 |
| Vanguard MStar Small Cap Value Index | 699K | 1.46% | -0.63% | Sep 2026 |
| Allspring Special Mid Cap Value Inst | 694K | 1.45% | -11.61% | Sep 2026 |
| iShares Core S&P 500 ETF | 637K | 1.33% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 620K | 1.29% | -0.78% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 589K | 1.23% | -0.25% | Oct 2026 |
| MFS Mid Cap Growth A | 526K | 1.10% | +9.81% | Sep 2026 |
| Fidelity Contrafund K6 | 440K | 0.92% | +13.09% | Sep 2026 |
| Ariel Fund Investor | 434K | 0.91% | -22.12% | Sep 2026 |
| iShares Biotechnology ETF | 368K | 0.77% | -0.32% | Oct 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 349K | 0.73% | +0.88% | Oct 2026 |
| T. Rowe Price Health Sciences | 301K | 0.63% | 0.00% | Sep 2026 |
| Vanguard Explorer Inv | 290K | 0.61% | -19.86% | Sep 2026 |
| T. Rowe Price Global Stock | 271K | 0.56% | +22.49% | Sep 2026 |
| Vanguard Selected Value Inv | 255K | 0.53% | -36.02% | Sep 2026 |
Top institutions holding CRL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 4.24M | 8.85% | +22.67% | Jun 2026 |
| BlackRock Inc | 3.80M | 7.93% | -1.57% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.15M | 6.57% | -1.65% | Jun 2026 |
| Amvescap Plc. | 2.98M | 6.23% | +24.51% | Jun 2026 |
| Harris Associates L.P. | 2.24M | 4.68% | +4.08% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.21M | 4.61% | -3.65% | Jun 2026 |
| Allspring Global Investments Holdings, LLC | 1.91M | 3.98% | -4.42% | Jun 2026 |
| State Street Corp | 1.86M | 3.89% | -0.50% | Jun 2026 |
| Ariel Investments, LLC | 1.51M | 3.14% | +4.29% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.51M | 3.14% | +33.79% | Jun 2026 |
| Geode Capital Management, LLC | 1.31M | 2.73% | +0.00% | Jun 2026 |
| Wellington Management Company LLP | 1.29M | 2.69% | -20.92% | Jun 2026 |
| Citadel Advisors Llc | 1.19M | 2.49% | -1.53% | Jun 2026 |
| Bank of America Corp | 1.17M | 2.45% | +3.31% | Jun 2026 |
| Earnest Partners LLC | 1.12M | 2.34% | +15.30% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 934K | 1.95% | -43.37% | Sep 2026 |
| Ameriprise Financial Inc | 881K | 1.84% | -20.57% | Jun 2026 |
| Neuberger Berman Group LLC | 863K | 1.80% | -1.34% | Jun 2026 |
| SEI Investments Co | 814K | 1.70% | +7.45% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 800K | 1.67% | -3.05% | Jun 2026 |
Charles River Laboratories company profile
- Company name
- Charles River Laboratories
- Ticker
- CRL.US
- Exchange
- USA Stocks
- Listed since
- Jun 23, 2000
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 18,300
- Fiscal year end
- December
- Address
- 251 Ballardvale Street, Wilmington, MA, United States, 01887
- Phone
- 781 222 6000
- Website
- criver.com
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Charles River Laboratories management
10- Ms. Birgit GirshickCEO & Director · born 1970
- Mr. Michael Gunnar KnellCorporate Senior VP & Chief Accounting Officer · born 1977
- Mr. Joseph W. LaPlume J.D.Corporate Executive Vice President of Corporate Development & Strategy · born 1974
- Ms. Victoria L. CreamerCorporate Executive VP & Chief People Officer · born 1970
- Mr. Glenn G. Coleman CPACorporate Executive VP & CFO · born 1968
- Mr. Mark MintzCorporate EVP, Chief Information Officer & Global Shared Services · born 1974
- Mr. Todd SpencerCorporate Vice President of Investor Relations
- Ms. Kerry DaileyCorporate Senior VP & Chief Legal Officer
- Ms. Amy E. CianciarusoCorporate Senior Vice President, Chief Communications Officer & Government Relations
- Dr. Brian F. Bathgate Ph.D.Corporate Senior Vice President of European Safety Assessment · born 1960